A 2-part, Open-label, Single-dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK-8189
Latest Information Update: 10 Oct 2023
At a glance
- Drugs MK 8189 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Feb 2022 Planned End Date changed from 31 Jan 2022 to 1 Mar 2022.
- 01 Feb 2022 Planned primary completion date changed from 31 Jan 2022 to 1 Mar 2022.